Impact of Coronavirus Disease 2019 on long-term renal function in patients with chronic kidney disease undergoing no renal replacement therapy

TIAN Qianqian; WU Qiuchan; FENG Yuanjun; ZHANG Zulong; LI Mei; ZHANG Xuan; XIE Moujin; QING Qunchao; LIU Lei

doi:10.7619/jcmp.20242826

Journal of Clinical Medicine in Practice > 2024 > 28(18): 86-89, 94. > DOI: 10.7619/jcmp.20242826

TIAN Qianqian, WU Qiuchan, FENG Yuanjun, ZHANG Zulong, LI Mei, ZHANG Xuan, XIE Moujin, QING Qunchao, LIU Lei. Impact of Coronavirus Disease 2019 on long-term renal function in patients with chronic kidney disease undergoing no renal replacement therapy[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 86-89, 94. DOI: 10.7619/jcmp.20242826

Citation:

PDF (1057 KB)

Impact of Coronavirus Disease 2019 on long-term renal function in patients with chronic kidney disease undergoing no renal replacement therapy

1.
Department of Nephrology and Rheumatology, Guizhou Aerospace Hospital, Zunyi, Guizhou, 563000
2.
Department of Nephrology, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001

More Information

Received Date: July 02, 2024
Revised Date: August 28, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the impact of Coronavirus Disease 2019 (COVID-19) on long-term renal function in patients with chronic kidney disease (CKD) who received no renal replacement therapy.
Methods
Thirty-nine CKD patients with an estimated glomerular filtration rate (eGFR) < 60 mL/(min·1.73 m²) at the time of COVID-19 diagnosis, admitted to Guizhou Aerospace Hospital from December 2022 to March 2023, were enrolled in the COVID-19 group. Additionally, 40 CKD patients without COVID-19 from September to December 2021, were included in control group. Changes in eGFR were compared between the two groups, and the temporal trend of eGFR in the COVID-19 group was analyzed using a mixed-effects linear model.
Results
No statistically significant differences were observed in eGFR levels at baseline, 1- and 3-month of follow-up between the COVID-19 and control groups (P>0.05). However, at 1 year of follow-up, the eGFR level in the COVID-19 group was significantly lower than that in the control group (P < 0.05). The mixed-effects linear model analysis revealed a decrease in eGFR by 1.84 mL/(min·1.73 m²) within 1 year of COVID-19 onset in the COVID-19 group, which inclined 4.62% from baseline, with the most significant decline (7.45%) observed among diabetic patients.
Conclusion
Patients with CKD who have not undergone renal replacement therapy experience a substantial decline in eGFR and worsened renal function within 1 year of COVID-19, necessitating close long-term renal function monitoring and timely interventions.
- chronic kidney disease,
- Coronavirus Disease 2019,
- estimated glomerular filtration rate,
- renal replacement therapy

FullText(HTML)

References (20)

References

[1]	WIERSINGA W J, RHODES A, CHENG A C, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019(COVID-19): a review[J]. JAMA, 2020, 324(8): 782-793. doi: 10.1001/jama.2020.12839
[2]	GUAN W J, NI Z Y, HU Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720. doi: 10.1056/NEJMoa2002032
[3]	OZTURK S, TURGUTALP K, ARICI M, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey[J]. Nephrol Dial Transplant, 2020, 35(12): 2083-2095. doi: 10.1093/ndt/gfaa271
[4]	KANG S H, KIM S W, KIM A Y, et al. Association between chronic kidney disease or acute kidney injury and clinical outcomes in COVID-19 patients[J]. J Korean Med Sci, 2020, 35(50): e434. doi: 10.3346/jkms.2020.35.e434
[5]	BOWE B, XIE Y, XU E, et al. Kidney outcomes in long COVID[J]. J Am Soc Nephrol, 2021, 32(11): 2851-2862. doi: 10.1681/ASN.2021060734
[6]	CARRIAZO S, MAS-FONTAO S, SEGHERS C, et al. Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study[J]. Clin Kidney J, 2022, 15(3): 432-441. doi: 10.1093/ckj/sfab248
[7]	CHENG Y C, LUO R, WANG K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19[J]. Kidney Int, 2020, 97(5): 829-838. doi: 10.1016/j.kint.2020.03.005
[8]	NUGENT J, AKLILU A, YAMAMOTO Y, et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19[J]. JAMA Netw Open, 2021, 4(3): e211095. doi: 10.1001/jamanetworkopen.2021.1095
[9]	ATIQUZZAMAN M, THOMPSON J R, SHAO S, et al. Long-term effect of COVID-19 infection on kidney function among COVID-19 patients followed in post-COVID-19 recovery clinics in British Columbia, Canada[J]. Nephrol Dial Transplant, 2023, 38(12): 2816-2825. doi: 10.1093/ndt/gfad121
[10]	KROLEWSKI A S, NIEWCZAS M A, SKUPIEN J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria[J]. Diabetes Care, 2014, 37(1): 226-234. doi: 10.2337/dc13-0985
[11]	WANNER C, HEERSPINK H J L, ZINMAN B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial[J]. J Am Soc Nephrol, 2018, 29(11): 2755-2769. doi: 10.1681/ASN.2018010103
[12]	NOJIMA J, MEGURO S, OHKAWA N, et al. One-year eGFR decline rate is a good predictor of prognosis of renal failure in patients with type 2 diabetes[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2017, 93(9): 746-754. doi: 10.2183/pjab.93.046
[13]	TANGRI N, STEVENS L A, GRIFFITH J, et al. A predictive model for progression of chronic kidney disease to kidney failure[J]. JAMA, 2011, 305(15): 1553-1559. doi: 10.1001/jama.2011.451
[14]	PAN X W, XU D, ZHANG H, et al. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis[J]. Intensive Care Med, 2020, 46(6): 1114-1116. doi: 10.1007/s00134-020-06026-1
[15]	BUONAGURO F M, ASCIERTO P A, MORSE G D, et al. Covid-19: time for a paradigm change[J]. Rev Med Virol, 2020, 30(5): e2134. doi: 10.1002/rmv.2134
[16]	HENDERSON L A, CANNA S W, SCHULERT G S, et al. On the alert for cytokine storm: immunopathology in COVID-19[J]. Arthritis Rheumatol, 2020, 72(7): 1059-1063. doi: 10.1002/art.41285
[17]	LI H, LIU L, ZHANG D Y, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses[J]. Lancet, 2020, 395(10235): 1517-1520. doi: 10.1016/S0140-6736(20)30920-X
[18]	TANG N, BAI H, CHEN X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy[J]. J Thromb Haemost, 2020, 18(5): 1094-1099. doi: 10.1111/jth.14817
[19]	TERPOS E, NTANASIS-STATHOPOULOS I, ELALAMY I, et al. Hematological findings and complications of COVID-19[J]. Am J Hematol, 2020, 95(7): 834-847. doi: 10.1002/ajh.25829
[20]	JANSEN J, REIMER K C, NAGAI J S, et al. SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids[J]. Cell Stem Cell, 2022, 29(2): 217-231. e8. doi: 10.1016/j.stem.2021.12.010

Cited By

Get Citation

PDF

XML

Article views (83) PDF downloads (6)

Turn off MathJax

Article Contents

Abstract

References

Impact of Coronavirus Disease 2019 on long-term renal function in patients with chronic kidney disease undergoing no renal replacement therapy

Abstract

References

Catalog

Export File

Citation

Format

Content